Geneserine is a naturally occurring alkaloid isolated from the African plant *Physostigma venenosum*. It is an acetylcholinesterase inhibitor, meaning it blocks the breakdown of acetylcholine, a neurotransmitter involved in muscle contraction and memory. This effect makes geneserine a potential treatment for conditions such as Alzheimer's disease and myasthenia gravis. However, its use is limited due to its toxicity. Research into geneserine focuses on understanding its pharmacological properties, potential therapeutic applications, and developing safer analogs.'
geneserine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 65719 |
CHEMBL ID | 123248 |
CHEBI ID | 4855 |
SCHEMBL ID | 1649922 |
MeSH ID | M0167864 |
Synonym |
---|
nsc340071 |
eserine oxide |
1,5-b]indol-6-ol, 2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-, methylcarbamate (ester), (4as-cis)- |
eserine aminoxide |
geneserine |
nsc-340071 |
pyrrolo[2, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), 1-oxide, (3as-cis)- |
C09176 |
bdbm10962 |
(4as,9as)-2,4a,9-trimethyl-2h,3h,4h,4ah,9h,9ah-indolo[3,2-e][1,2]oxazin-6-yl n-methylcarbamate |
geneserine oxazine |
einecs 247-111-2 |
(4as,9as)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino(6,5-b)indol-6-ylmethylcarbamate |
eseridine [inn] |
eseridina [spanish] |
eseridinum [latin] |
[(4as,9as)-2,4a,9-trimethyl-4,9a-dihydro-3h-oxazino[6,5-b]indol-6-yl] n-methylcarbamate |
chebi:4855 , |
CHEMBL123248 |
D07914 |
eseridine (inn) |
unii-lw9s78l4m8 |
eseridina |
lw9s78l4m8 , |
eseridinum |
geneserine [mi] |
eseridine [who-dd] |
SCHEMBL1649922 |
eseridin |
[(4as,9as)-2,4a,9-trimethyl-4,9a-dihydro-3h-oxazino[6,5-b]indol-6-yl]n-methylcarbamate |
Q27106509 |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Cholinesterase | Homo sapiens (human) | IC50 (µMol) | 0.0810 | 0.0000 | 1.5599 | 10.0000 | AID1796572 |
Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 0.1040 | 0.0000 | 0.9332 | 10.0000 | AID1796572; AID31163 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID44285 | Ex vivo inhibition of human plasma Butyrylcholinesterase. | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17 | Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. |
AID31163 | Ex vivo inhibition of human erythrocyte Acetylcholinesterase. | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17 | Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. |
AID234643 | Selectivity at AChE and BChE | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17 | Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. |
AID1796572 | Cholinesterase Inhibition Assay from Article 10.1021/jm010491d: \\Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.\\ | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17 | Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.40) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |